Themis Medicare Limited (THEMISMED.NS)
INR 120.32
(-13.58%)
INR 120.32
(-13.58%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.66 Billion INR | 10.21% |
| 2022 | 5.13 Billion INR | 20.14% |
| 2021 | 4.27 Billion INR | 15.26% |
| 2020 | 3.71 Billion INR | 6.07% |
| 2019 | 3.49 Billion INR | 11.4% |
| 2018 | 3.14 Billion INR | 2.9% |
| 2017 | 3.05 Billion INR | -1.45% |
| 2016 | 3.09 Billion INR | 12.18% |
| 2015 | 2.76 Billion INR | -1.13% |
| 2014 | 2.79 Billion INR | -1.97% |
| 2013 | 2.84 Billion INR | 4.21% |
| 2012 | 2.73 Billion INR | -2.21% |
| 2011 | 2.79 Billion INR | -4.9% |
| 2010 | 2.93 Billion INR | 6.49% |
| 2009 | 2.76 Billion INR | -6.22% |
| 2008 | 2.94 Billion INR | 7.93% |
| 2007 | 2.72 Billion INR | 17.87% |
| 2006 | 2.31 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 6.02 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 5.66 Billion INR | 10.21% |
| 2023 Q4 | 5.66 Billion INR | 0.0% |
| 2023 Q2 | 5.48 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 4.67 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 5.13 Billion INR | 20.14% |
| 2022 Q4 | 5.13 Billion INR | 0.0% |
| 2021 Q4 | 4.27 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 4.02 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 4.27 Billion INR | 15.26% |
| 2020 Q2 | 3.56 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 3.71 Billion INR | 6.07% |
| 2020 Q4 | 3.71 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 3.24 Billion INR | 0.0% |
| 2019 FY | 3.49 Billion INR | 11.4% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 3.49 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 3.14 Billion INR | 0.0% |
| 2018 FY | 3.14 Billion INR | 2.9% |
| 2017 FY | 3.05 Billion INR | -1.45% |
| 2017 Q4 | 3.05 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 2.93 Billion INR | 0.0% |
| 2016 Q4 | 3.09 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 3.09 Billion INR | 12.18% |
| 2016 Q2 | 3.09 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 FY | 2.76 Billion INR | -1.13% |
| 2015 Q4 | 2.76 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 2.8 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q4 | 2.79 Billion INR | 0.0% |
| 2014 FY | 2.79 Billion INR | -1.97% |
| 2013 FY | 2.84 Billion INR | 4.21% |
| 2012 Q4 | 2.73 Billion INR | 0.0% |
| 2012 Q2 | 4.63 Billion INR | 0.0% |
| 2012 FY | 2.73 Billion INR | -2.21% |
| 2011 FY | 2.79 Billion INR | -4.9% |
| 2010 FY | 2.93 Billion INR | 6.49% |
| 2009 FY | 2.76 Billion INR | -6.22% |
| 2008 FY | 2.94 Billion INR | 7.93% |
| 2007 FY | 2.72 Billion INR | 17.87% |
| 2006 FY | 2.31 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 91.212% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -283.539% |
| FDC Limited | 24.68 Billion INR | 77.05% |
| Gufic Biosciences Limited | 10.92 Billion INR | 48.156% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 95.095% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 74.149% |
| Orchid Pharma Limited | 15.53 Billion INR | 63.548% |
| Alkem Laboratories Limited | 155.74 Billion INR | 96.363% |
| Bajaj HealthCare Limited | 7.65 Billion INR | 25.971% |
| Brooks Laboratories Limited | 904.45 Million INR | -526.252% |
| Eris Lifesciences Limited | 70.48 Billion INR | 91.964% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 80.129% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | 75.862% |
| Innova Captab Limited | 13.2 Billion INR | 57.118% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -160.928% |
| Wanbury Limited | 3.43 Billion INR | -64.899% |
| Lupin Limited | 239.97 Billion INR | 97.64% |
| Aarti Drugs Limited | 24.32 Billion INR | 76.713% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 78.064% |
| Albert David Limited | 4.97 Billion INR | -13.74% |
| Alembic Limited | 23.28 Billion INR | 75.677% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -1103.025% |
| Hester Biosciences Limited | 6.62 Billion INR | 14.483% |
| Hikal Limited | 24.87 Billion INR | 77.226% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 51.385% |
| Ind-Swift Limited | 6.54 Billion INR | 13.454% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 74.763% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -135.946% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | 19.117% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -69.879% |
| Medico Remedies Limited | 961.95 Million INR | -488.819% |
| Morepen Laboratories Limited | 12.93 Billion INR | 56.201% |
| Procter & Gamble Health Limited | 7.94 Billion INR | 28.695% |
| RPG Life Sciences Limited | 5.12 Billion INR | -10.441% |
| Sigachi Industries Limited | 6.94 Billion INR | 18.402% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 99.337% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 74.872% |
| Unichem Laboratories Limited | 31.69 Billion INR | 82.128% |
| Vaishali Pharma Limited | 799.55 Million INR | -608.413% |
| Venus Remedies Limited | 6.26 Billion INR | 9.638% |
| Windlas Biotech Limited | 6.26 Billion INR | 9.548% |
| ZIM Laboratories Limited | 4.46 Billion INR | -26.765% |
| Sakar Healthcare Limited | 3.88 Billion INR | -45.736% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 98.743% |
| Divi's Laboratories Limited | 154.7 Billion INR | 96.339% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 47.458% |
| Mankind Pharma Limited | 119.63 Billion INR | 95.265% |
| Sequent Scientific Limited | 15.4 Billion INR | 63.229% |
| Laurus Labs Limited | 83.87 Billion INR | 93.247% |
| Neuland Laboratories Limited | 18.32 Billion INR | 69.092% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 85.819% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 96.055% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 98.066% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -54.391% |
| Wockhardt Limited | 76.49 Billion INR | 92.595% |
| Bal Pharma Limited | 3.2 Billion INR | -76.79% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 98.538% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 53.338% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -457.436% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | 79.001% |
| Shilpa Medicare Limited | 30.93 Billion INR | 81.688% |
| Valiant Laboratories Limited | 3.42 Billion INR | -65.287% |
| Ajanta Pharma Limited | 46.38 Billion INR | 87.789% |
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | -85.715% |
| Granules India Limited | 55.2 Billion INR | 89.741% |
| Medicamen Biotech Limited | 2.94 Billion INR | -92.317% |
| Ipca Laboratories Limited | 111.01 Billion INR | 94.898% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -39.972% |
| Piramal Enterprises Limited | 826.05 Billion INR | 99.314% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 96.239% |
| NATCO Pharma Limited | 69.06 Billion INR | 91.799% |
| Suven Life Sciences Limited | 2.84 Billion INR | -98.811% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -217.9% |
| Strides Pharma Science Limited | 58.39 Billion INR | 90.301% |
| Indoco Remedies Limited | 21.44 Billion INR | 73.59% |
| Alpa Laboratories Limited | 1.82 Billion INR | -210.158% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -275.437% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -9.975% |